Jaguar Health公布第四季度业绩

2026-04-08 12:41

Jaguar Health press release (JAGX): Q4 Revenue of $3.2M (-8.6% Y/Y).
Net loss attributable to common shareholders increased by approximately $15.1 million, from $38.5 million in the year ended December 31, 2024 to $53.6 million in 2025.
Mytesi prescription volume decreased approximately 3.7% in the year 2025 over 2024, by approximately 5.8% in the fourth quarter of 2025 over the third quarter of 2025, and by approximately 12.2% in the fourth quarter of 2025 over the fourth quarter of 2024.
For the fourth quarter of 2025, the Company recognized license fees of $42,500 from a securities purchase agreement with a European partner.
Revenues for the non-prescription Neonorm products were minimal for the fourth quarters of 2025 and 2024.

More on Jaguar Health